Medicines During Stroke Rehabilitation: Prevention, Symptom Relief and Evidence Limits

Medication during stroke rehabilitation often comes from several specialties. Some medicines prevent another event, some manage blood pressure or lipids, and others address pain, spasticity or depression. They may have an important role without making walking visibly better that day. Understanding a prescription starts with its purpose, intended course, monitoring and the clinician responsible for changes. It is misleading to call every item a nerve-recovery medicine, and taking tablets cannot replace needed rehabilitation.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The mechanism of an ischemic stroke influences prevention. Non-cardioembolic disease commonly involves an antiplatelet strategy, while atrial fibrillation may require anticoagulation. The choice does not follow directly from the severity of paralysis. Other illnesses may create independent indications. On transfer to rehabilitation, distinguish medicines already stopped, those still being taken and those planned but not yet started, rather than combine several prescriptions without reconciliation.[S11][S12]
Post-stroke depression deserves assessment, with psychological treatment and medication considered as appropriate. Persistent low mood, loss of interest and related symptoms should not go untreated because the patient fears interference with rehabilitation. Treating depression is, however, a different question from prescribing a drug to everyone to improve movement. The intended reason should be explicit.[S9]
Provide the receiving team with all prescriptions, actual administration records, allergies and recent tests, including medicines unavailable where the patient normally lives. Generic names, brands, formulations and strengths encountered in China may differ from previous supplies; replacements require clinical verification. Establish access after returning home, necessary monitoring and the professional responsible for renewals. Availability needs confirmation from the specific hospital and follow-up service.[S3][S44]

Quick answer

Full guide

Label the different purposes on the medication list

The mechanism of an ischemic stroke influences prevention. Non-cardioembolic disease commonly involves an antiplatelet strategy, while atrial fibrillation may require anticoagulation. The choice does not follow directly from the severity of paralysis. Other illnesses may create independent indications. On transfer to rehabilitation, distinguish medicines already stopped, those still being taken and those planned but not yet started, rather than combine several prescriptions without reconciliation.[S11][S12]

Record generic name, formulation, actual dose, timing, indication and the reason for the last change. A different brand may contain the same ingredient, while similar ingredients are not automatically interchangeable. If aphasia, memory difficulty or impaired hand use affects medication management, identify who collects, organizes and checks doses. A theoretically correct prescription that cannot be carried out needs practical review with the clinician and pharmacist.[S3][S17]

More antiplatelet medicines are not automatically better

Aspirin, clopidogrel and other antiplatelet options can be used for prevention in suitable non-cardioembolic stroke. Selected acute presentations may involve a limited course of two agents, but this is not a reason for every patient to remain on both indefinitely. The combination and duration depend on the event, vessels, other indications and bleeding risk. The stroke team should specify the later regimen and how the transition will occur.[S11]

If discharge instructions describe a temporary combination, establish its review or stopping date. Absence of recurrent symptoms does not justify ending it early, and fear of another stroke is not a reason to add a third medicine. Bleeding or a suspected adverse reaction requires medical advice about severity and management. The preventive benefit and treatment risk need to be considered together rather than left for the patient to weigh without help.[S11]

Discuss anticoagulation separately when atrial fibrillation is involved

Anticoagulants and antiplatelet agents act differently and cannot be exchanged simply because both address clotting. Direct oral anticoagulants may be appropriate for many people with nonvalvular atrial fibrillation, while mechanical heart valves and other circumstances have different requirements. Kidney function, interacting drugs, bleeding history and adherence influence selection. Warfarin requires relevant coagulation monitoring; direct oral agents still require clinical follow-up and are not a way to avoid all checks.[S12]

Randomized evidence has changed the discussion of starting treatment. In the 2024 OPTIMAS trial, beginning a direct oral anticoagulant within four days of AF-related acute ischemic stroke was noninferior to beginning on days seven to fourteen for the study's 90-day composite outcome. This supports reconsideration of a universal delay, but it is not a calendar instruction for every patient. Imaging, hemorrhagic transformation, clinical stability and contraindications still require the treating team's judgment.[S45]

Blood pressure and lipid treatment address future vascular risk

Blood pressure management is important after stroke. If substantial dizziness or position-related symptoms occur during rehabilitation, provide the readings, activity and medication timing to the clinician. Medication, hydration, posture or another factor may be involved. One measurement should not trigger an unsupervised dose change. Acute and stable-phase targets may differ, with particular care needed for selected hemodynamic problems.[S52]

Lipid-lowering treatment does more than remove an abnormal marker on a laboratory report. Statins and additional agents when indicated reduce future vascular risk. An improved result does not establish that the original risk has permanently disappeared. Muscle symptoms or other concerns should prompt assessment of whether medication contributes and whether adjustment or an alternative is appropriate, instead of abandonment of the entire prevention strategy. Personal targets belong in the follow-up plan.[S51]

Identify the consequence of spasticity before treating it

Increased tone can cause pain, hygiene difficulty, abnormal joint position or limitations in activity. Defining the goal helps the clinician choose local or systemic treatment. Oral medicines such as baclofen may be considered for suitable generalized spasticity, with attention to drowsiness, fatigue or weakness that could affect activity. Seeking lower tone alone can overlook a change in support previously used for standing or transferring.[S27][S2]

If treatment makes palm cleaning easier but the person sleepier and harder to transfer, report both effects. Infection, pain and constipation may aggravate spasticity, making treatment of triggers important alongside medication review. Complex, persistent or poorly tolerated problems need a specialist service rather than repeated self-directed dose increases. Changes to long-term therapy, including stopping, should be clinician-directed to avoid problems from abrupt alteration.[S27][S35]

Botulinum toxin addresses selected focal problems

For appropriately assessed focal spasticity, botulinum toxin injection can form part of a goal-directed program. Identify the muscles considered, the desired care or activity improvement and the therapy to accompany it. Its role differs from increasing strength. Injection cannot guarantee voluntary grasp or independent walking. Product-specific dosing and administration require a suitably experienced clinician rather than transfer of assumptions between preparations.[S27][S2]

When discussing this in China, verify the precise product and authorized indication. A brand or dose in an overseas guideline is not automatically the correct local prescription. Ask how benefit will be reviewed and when repeat treatment would be inappropriate. If easier hygiene is the primary goal, assess hygiene, pain and assistance. An additional hope of active movement requires its own explanation of practice and measurement.[S27][S44]

Select antidepressant treatment for the clinical need

Post-stroke depression deserves assessment, with psychological treatment and medication considered as appropriate. Persistent low mood, loss of interest and related symptoms should not go untreated because the patient fears interference with rehabilitation. Treating depression is, however, a different question from prescribing a drug to everyone to improve movement. The intended reason should be explicit.[S9]

A 2024 individual-participant analysis of FOCUS, AFFINITY and EFFECTS included approximately 5,900 people and found no improvement in overall functional recovery from routine fluoxetine under the study regimen. Seizures, injurious falls, fractures and hyponatremia were more frequent. This does not negate treatment of established depression, but it does not support fluoxetine as a universal motor-recovery medicine. Anyone already taking it should clarify the indication with the prescriber rather than stop abruptly on the basis of a summary.[S46][S9]

Pain medicines depend on the type of pain

Pain after stroke can arise from the shoulder, muscles and joints, spasticity or central neuropathic mechanisms. These need different approaches. Canadian 2025 guidance considers central post-stroke pain after other causes have been excluded, with options including gabapentin or pregabalin and other appropriate medicines. The labels anticonvulsant or antidepressant do not mean that everyone receiving such an agent for pain has epilepsy or depression.[S47]

Review pain, sleep and activity together. Drowsiness or dizziness may affect falling risk, while kidney function and other medicines can alter selection. If treatment fails to meet the goal, the clinician should reconsider dose, course, diagnosis and alternatives. Do not independently combine several sedating agents. Relief that permits meaningful participation is more useful than an isolated change in a pain score accompanied by difficulty functioning.[S47][S20]

Fatigue does not automatically require a stimulant

Fatigue assessment considers sleep, mood, pain, medication effects and other treatable factors. Selected medicines may be considered in particular circumstances, but not as routine treatment for everyone. Canadian 2025 guidance also does not support using an antidepressant solely for fatigue without another indication. Recording the most difficult times, recovery after activity and sleep patterns can help define the problem.[S18]

Reducing unnecessary medication burden, changing activity pacing and addressing sleep may contribute to the plan, with clinician review of each item. A family should not stop a drug that appears sedating when it may be controlling another condition. If a change is needed, establish the observations, review date and contact for problems. Drug and non-drug measures can work together without directing all effort toward finding another prescription.[S18][S3]

Do not extend acute Chinese drug studies automatically to longstanding disability

Patients considering care in China may encounter information about butylphthalide or edaravone dexborneol. The study population and treatment stage matter. The 2023 BAST trial evaluated acute ischemic stroke receiving thrombolysis and/or endovascular treatment and found a functional outcome benefit with butylphthalide under its study conditions. It does not directly establish that repeated courses years later repair existing disability. The same drug name can be discussed in quite different clinical situations.[S48]

Chinese approved information for edaravone dexborneol sublingual tablets addresses neurological symptoms, daily activity and dysfunction caused by acute ischemic stroke, with approval dated December 1, 2024. TASTE-SL also concerned acute treatment. The label includes contraindications and monitoring, including severe renal impairment, hypersensitivity and pregnancy-related restrictions. Convenient administration does not make it a self-selected long-term rehabilitation medicine. Chinese approval also does not establish stock at every hospital.[S49][S50][S54]

Resolve administration when swallowing is impaired

Whether a tablet can be swallowed, divided, crushed or given through a tube depends on the formulation. Enteric-coated, modified-release and sublingual products should not be handled simply according to appearance. The swallowing team determines current oral safety, while the clinician and pharmacist establish an appropriate medicine route. Do not repeatedly use water to test tablet swallowing or combine every medicine into one portion of food.[S7]

A sublingual product should not automatically be used like an ordinary oral tablet. The reviewed Chinese edaravone dexborneol sublingual label, for example, specifies sublingual administration and warns against directly swallowing an undisintegrated tablet. Whether the patient can use that method still requires professional judgment. The exact administration instructions should accompany transfer records so that the next caregiver does not act on the drug name alone.[S50][S7]

Maintain one reconciled prescription across Chinese and home services

Provide the receiving team with all prescriptions, actual administration records, allergies and recent tests, including medicines unavailable where the patient normally lives. Generic names, brands, formulations and strengths encountered in China may differ from previous supplies; replacements require clinical verification. Establish access after returning home, necessary monitoring and the professional responsible for renewals. Availability needs confirmation from the specific hospital and follow-up service.[S3][S44]

Before discharge, obtain the final active list and identify discontinued medicines so that old boxes do not re-enter the routine. Prevention and symptom treatment may have different review schedules. Changes in activity, pain and suspected adverse effects should reach the responsible prescriber. Coordinating medication with rehabilitation helps manage recurrence risk while preserving alertness, comfort and the ability to take part in daily life.[S1][S3]